

LESOTHO – PENTAVALENT VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme

1. Country: Lesotho			
2. Grant Number: 1215-LSO-04c-X			
3. Date of Decision Letter: 15 December 2014			
4. Date of the Partnership Framework Agreement: 30 November 2012			
5. Programme Title: New Vaccine Support			
6. Vaccine type: Pentavalent			
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID			
8. Programme Duration⁶: 2008 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2008-2014	2015	Total ⁷
Programme Budget (US\$)	US\$2,188,161 ⁸	US\$83,500	US\$2,271,661
10. Vaccine Introduction Grant: n/a			
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁹			
Type of supplies to be purchased with Gavi funds in each year	2008-2014	2015	
Number of Pentavalent vaccines doses		41,500	
Number of AD syringes		22,800	
Number of safety boxes		275	
Annual Amounts (US\$)	US\$2,188,161 ¹⁰	US\$83,500	
12. Procurement agency: UNICEF			
13. Self-procurement: n/a			

⁶ This is the entire duration of the programme.

⁷ This is the total amount endorsed by Gavi for the entire duration of the programme.

⁸ This is the consolidated amount for all previous years.

⁹ This is the amount that Gavi has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

¹⁰ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 1215-LSO-04c-X-C

According to the Co-Financing Policy, the Country falls within the group Intermediate. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2015
Number of vaccine doses	27,500
Number of AD syringes	15,100
Number of safety boxes	175
Value of vaccine doses (US\$)	US\$52,568
Total Co-Financing Payments (US\$) (including freight)	US\$55,500

15. Operational support for campaigns: n/a

16. Additional documents to be delivered for future disbursements:

Reports, documents and other deliverables	Due dates
Annual Progress Report or its equivalent	15 May 2015

17. Financial Clarifications: The Country shall provide the following clarifications to Gavi*: n/a

**Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

18. Other conditions: Provide an update on the implementation of recommendations of the aide-memoire.

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

15 December 2014

LESOTHO – PNEUMOCOCCAL VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme

1. Country: Lesotho				
2. Grant Number: 1216-LSO-12c-X				
3. Date of Decision Letter: 15 December 2014				
4. Date of the Partnership Framework Agreement: 30 November 2012				
5. Programme Title: New Vaccine Support				
6. Vaccine type: Pneumococcal				
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID				
8. Programme Duration¹: 2014 - 2016				
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):				
	2014	2015	2016	Total ²
Programme Budget (US\$)	US\$619,000 ³	US\$125,000	US\$466,500	US\$1,210,500
10. Vaccine Introduction Grant: n/a				
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴				
Type of supplies to be purchased with Gavi funds in each year	2014	2015		
Number of Pneumococcal vaccines doses		21,600		
Number of AD syringes		21,900		
Number of safety boxes		250		
Annual Amounts (US\$)	US\$619,000 ⁵	US\$125,000		
12. Procurement agency: UNICEF				

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

⁵ This is the consolidated amount for all previously approved years.

13. Self-procurement: n/a		
14. Co-financing obligations: Reference code: 1216-LSO-12c-X-C		
According to the Co-Financing Policy, the Country falls within the group Intermediate. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.		
Type of supplies to be purchased with Country funds in each year	2015	2016
Number of vaccine doses	3,600	9,000
Number of AD syringes	2,900	
Number of safety boxes	50	
Value of vaccine doses (US\$)	US\$9,889	
Total Co-Financing Payments (US\$) (including freight)	US\$11,000	US\$29,500
15. Operational support for campaigns: n/a		
16. Additional documents to be delivered for future disbursements:		
Reports, documents and other deliverables	Due dates	
Annual Progress Report or its equivalent	15 May 2015	
17. Financial Clarifications: The Country shall provide the following clarifications to Gavi*: n/a		
<i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i>		
18. Other conditions: Provide an update on the implementation of recommendations of the aide-memoire.		

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
15 December 2014